ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

タンパク質、抗体、アッセイキット

タンパク質カタログ

輸入に関する法規制チェックは、御見積のご依頼をいただいた際に行います。
法規制によっては、定価として記載の価格に追加の費用が発生する場合や供給出来ない場合がございますので、あらかじめご了承ください。

サプライヤー
AcroBioSystems
カタログNo.
HL1-H82E6
製品名称
Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Monomer, MALS & SPR verified)
タンパク質名
HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQC)
Species
Human
HOST
HEK293
25ug: 33,500円
お問い合わせ
200ug: 187,600円
お問い合わせ

Overview

Synonyms -
Characteristics Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide.
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 36.3 kDa and 13.8 kDa. The protein migrates as 40-43 kDa and 13 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level N/A
Purity 95%
Description NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients.?The Human HLA-A*0201 NY-ESO-1 (SLLMWITQC) complex protein is a complex of HLA-A*0201 of?the MHC Class I, B2M and SLLMWITQC peptide of the NY-ESO-1.
Reference -
URL https://www.acrobiosystems.com/products/protein/hla-a-02:01-b2m-ny-eso-1-sllmwitqc-human-hl1-h82e6

お問い合わせリスト(-)

お問い合わせフォーム